1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,020 | 4,060 | 17.07. | |
| 3,960 | 4,120 | 17.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Cytek Biosciences, Inc.: Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement | 1 | GlobeNewswire (USA) | ||
| Mi | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.06. | Cytek Biosciences, Inc.: Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 | 1 | GlobeNewswire (USA) | ||
| 02.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Earnings Call Transkript: Cytek Biosciences meldet Umsatzwachstum für Q1 2026, verfehlt aber Gewinnprognose | 1 | Investing.com Deutsch | ||
| 13.05. | Stephens cuts Cytek Biosciences stock price target on elevated costs | 1 | Investing.com | ||
| 13.05. | Cytek Biosciences: Stephens senkt Kursziel wegen hoher Kosten | 1 | Investing.com Deutsch | ||
| 08.05. | Cytek reaffirms $205M-$212M 2026 revenue outlook as U.S. growth rebounds | 5 | Seeking Alpha | ||
| 07.05. | Cytek Biosciences GAAP EPS of -$0.15 misses by $0.05, revenue of $44.1M misses by $0.2M | 2 | Seeking Alpha | ||
| 07.05. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cytek Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.03. | Singapore Facility powers Cytek's Asia-Pacific expansion | 1 | Singapore Business Review | ||
| 09.03. | Cytek Biosciences, Inc.: Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact | 1 | GlobeNewswire (USA) | ||
| 04.03. | Cytek Biosciences auf der TD Cowen Gesundheitskonferenz: Einblicke in die strategische Wachstumsplanung | 2 | Investing.com Deutsch | ||
| 27.02. | Cytek Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.02. | Cytek Biosciences outlines $205M-$212M 2026 revenue target amid record Q4 and growth in recurring revenue | 2 | Seeking Alpha | ||
| 26.02. | Cytek Biosciences: Rekordumsatz im vierten Quartal, Gewinnziel jedoch deutlich verfehlt | 1 | Investing.com Deutsch | ||
| 26.02. | Cytek Biosciences GAAP EPS of -$0.34 misses by $0.30, revenue of $62.1M beats by $3.3M | 1 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,009 | +9,52 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,450 | +3,38 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| CLINUVEL | 6,190 | +1,04 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| EDITAS MEDICINE | 2,580 | +2,79 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,102 | +2,04 % | CARDIOL THERAPEUTICS INC ruhig im strategischen Fokus | ||
| ASEP MEDICAL | 0,050 | +21,95 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,540 | -1,55 % | Cellectar publishes phase 1 data on multiple myeloma treatment | ||
| CYTODYN | 0,198 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,789 | +3,68 % | CARDIFF ONCOLOGY INC im strukturellen Gleichgewicht | ||
| EMERGENT BIOSOLUTIONS | 6,670 | -0,74 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,670 | -1,06 % | Will Recent Setbacks Impact Growth Prospects of DNLI Stock? | ||
| CEL-SCI | 1,000 | 0,00 % | CEL-SCI launches confirmatory study for head and neck cancer drug | ||
| CYTOKINETICS | 68,32 | -2,76 % | Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet | ||
| COHERUS ONCOLOGY | 1,220 | +1,41 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,240 | +1,12 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen |
CYTEK BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-0,51 %) liegt der Kurs bei 3,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.